We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Ingevity Stock to Your Portfolio
Read MoreHide Full Article
Ingevity Corporation’s (NGVT - Free Report) stock looks promising at the moment. Its shares have popped roughly 40% over the past three months. NGVT is expected to benefit from the strategic repositioning of its Performance Chemicals segment, strategic acquisitions and actions to drive growth.
We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it is poised to carry the momentum ahead.
Let's see what makes NGVT stock an attractive investment option at the moment.
NGVT’s Earnings Estimates Northbound
Earnings estimates for NGVT for 2024 have been going up over the past 60 days, reflecting analysts’ optimism. The Zacks Consensus Estimate for the current year has increased by 15.9%.
NGVT’s Positive Earnings Surprise History
Ingevity has outpaced the Zacks Consensus Estimate in three of the trailing four quarters. In this time frame, it has delivered an earnings surprise of roughly 95.4%, on average.
Ingevity’s Superior Return on Equity (ROE)
ROE is a measure of a company’s efficiency in utilizing shareholder’s funds. ROE for the trailing 12-months for Ingevity is 24.5%, above the industry’s level of 16.1%.
Strategic Repositioning and Acquisitions to Aid NGVT
Ingevity is taking several actions to expand capacity and drive long-term growth. It remains committed to investing organically. Ingevity is also committed to capturing the maximum value for its products.
The company is expected to benefit from the repositioning of its Performance Chemicals segment, which is aimed at lowering exposure to lower-margin end markets. The move includes consolidating segment operations at its North Charleston facility by moving oleo chemical refining to the North Charleston site’s secondary refinery as well as the closure of its Crossett facility. These actions further simplify the segment’s manufacturing footprint and create significant cost savings. NGVT expects this manufacturing consolidation to result in around $20-$25 million in annual savings beginning in 2025.
During the third quarter, the company began to notice the benefits of the repositioning. Ingevity’s focus over the next few quarters will be on execution to ensure that it maximizes the benefits of its approach. Operational improvements leading to lower input costs and better manufacturing efficiency are also aiding performance in its Performance Materials unit.
The acquisition of the Capa caprolactone business enabled the company with a new technology platform to drive revenue and earnings growth. Capa has a strong and market-leading business that focuses on high-growth end-use applications. NGVT, in July 2024, expanded its Capa caprolactone distribution network by selecting Ultrapolymers Group as the distributor for Capa Bioplastics in Europe. The acquisition of Ozark Materials has also strengthened the company’s position in the paving construction industry.
The Zacks Consensus Estimate for Methanex’s current-year earnings has increased by 20.7% in the past 60 days. MEOH beat the consensus estimate in each of the last four quarters with the average surprise being 101%. Its shares have gained roughly 7% in the past year.
The Zacks Consensus Estimate for Axalta Coating’s current year earnings is pegged at $2.15, indicating a rise of 36.9% from year-ago levels. The Zacks Consensus Estimate for AXTA’s current year earnings has increased 3.9% in the past 60 days. The stock has rallied around 17% in the past year.
DuPont beat the consensus estimate in each of the last four quarters with the average earnings surprise being 12.9%. DD’s shares have gained roughly 14% in the past year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Add Ingevity Stock to Your Portfolio
Ingevity Corporation’s (NGVT - Free Report) stock looks promising at the moment. Its shares have popped roughly 40% over the past three months. NGVT is expected to benefit from the strategic repositioning of its Performance Chemicals segment, strategic acquisitions and actions to drive growth.
We are positive on the company’s prospects and believe that the time is right for you to add the stock to the portfolio as it is poised to carry the momentum ahead.
Let's see what makes NGVT stock an attractive investment option at the moment.
NGVT’s Earnings Estimates Northbound
Earnings estimates for NGVT for 2024 have been going up over the past 60 days, reflecting analysts’ optimism. The Zacks Consensus Estimate for the current year has increased by 15.9%.
NGVT’s Positive Earnings Surprise History
Ingevity has outpaced the Zacks Consensus Estimate in three of the trailing four quarters. In this time frame, it has delivered an earnings surprise of roughly 95.4%, on average.
Ingevity’s Superior Return on Equity (ROE)
ROE is a measure of a company’s efficiency in utilizing shareholder’s funds. ROE for the trailing 12-months for Ingevity is 24.5%, above the industry’s level of 16.1%.
Strategic Repositioning and Acquisitions to Aid NGVT
Ingevity is taking several actions to expand capacity and drive long-term growth. It remains committed to investing organically. Ingevity is also committed to capturing the maximum value for its products.
The company is expected to benefit from the repositioning of its Performance Chemicals segment, which is aimed at lowering exposure to lower-margin end markets. The move includes consolidating segment operations at its North Charleston facility by moving oleo chemical refining to the North Charleston site’s secondary refinery as well as the closure of its Crossett facility. These actions further simplify the segment’s manufacturing footprint and create significant cost savings. NGVT expects this manufacturing consolidation to result in around $20-$25 million in annual savings beginning in 2025.
During the third quarter, the company began to notice the benefits of the repositioning. Ingevity’s focus over the next few quarters will be on execution to ensure that it maximizes the benefits of its approach. Operational improvements leading to lower input costs and better manufacturing efficiency are also aiding performance in its Performance Materials unit.
The acquisition of the Capa caprolactone business enabled the company with a new technology platform to drive revenue and earnings growth. Capa has a strong and market-leading business that focuses on high-growth end-use applications. NGVT, in July 2024, expanded its Capa caprolactone distribution network by selecting Ultrapolymers Group as the distributor for Capa Bioplastics in Europe. The acquisition of Ozark Materials has also strengthened the company’s position in the paving construction industry.
Ingevity Corporation Price and Consensus
Ingevity Corporation price-consensus-chart | Ingevity Corporation Quote
NGVT’s Zacks Rank & Other Key Picks
NGVT currently carries a Zacks Rank #2 (Buy).
Other top-ranked stocks in the Basic Materials space are Methanex Corporation (MEOH - Free Report) , Axalta Coating Systems Ltd. (AXTA - Free Report) and DuPont de Nemours, Inc. (DD - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Methanex’s current-year earnings has increased by 20.7% in the past 60 days. MEOH beat the consensus estimate in each of the last four quarters with the average surprise being 101%. Its shares have gained roughly 7% in the past year.
The Zacks Consensus Estimate for Axalta Coating’s current year earnings is pegged at $2.15, indicating a rise of 36.9% from year-ago levels. The Zacks Consensus Estimate for AXTA’s current year earnings has increased 3.9% in the past 60 days. The stock has rallied around 17% in the past year.
DuPont beat the consensus estimate in each of the last four quarters with the average earnings surprise being 12.9%. DD’s shares have gained roughly 14% in the past year.